Dup15q syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix

Dup15q syndrome therapies, such as Bexicaserin, UBE3A (ASO), and others, are expected to boost the Dup15q syndrome Market in the upcoming years.

DelveInsight has launched a new report on "Dup15q syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Dup15q syndrome, historical and forecasted epidemiology as well as the Dup15q syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Dup15q syndrome market report @ https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Dup15q syndrome Market Report:

Dup15q Syndrome is classified into two main subtypes: isodicentric chromosome 15 (idic[15]), which makes up roughly 80% of cases, and interstitial 15q duplication (int dup[15]), accounting for about 20%. In the U.S., the condition affects approximately 1 in 14,000 individuals, and it's notably prevalent among individuals with autism spectrum disorder (ASD), impacting around 1 in 500. As of 2024, Japan reported an estimated 8,900 prevalent cases of Dup15q syndrome.
In March 2025, Quiver Bioscience partnered with the Dup15q Alliance to advance an antisense oligonucleotide (ASO) therapy targeting the overexpression of the UBE3A gene, a key factor in Dup15q syndrome. This collaboration utilizes Quiver's Genomic Positioning System, integrating AI and human neuronal models to expedite drug discovery. The ASO therapy is currently in preclinical stages .
In 2024, the FDA issued a recall for certain batches of Clonazepam Orally Disintegrating Tablets due to potential mislabeling of product strength.
Currently, drug development for Dup15q syndrome remains limited. Few therapies are under clinical evaluation, including bexacaserin by Lundbeck for Developmental and Epileptic Encephalopathies (DEEs). Roche recently removed basmisanil (RG1662) from its pipeline for Dup15q, raising concerns about future market growth. Takeda had been developing soticlestat for Dup15q-related epilepsy, but following unsuccessful trials in Dravet and Lennox-Gastaut syndromes, the company discontinued the program in January 2025.
Some companies, like Quiver Bioscience, are in early preclinical stages, while others are exploring indirect opportunities. For example, Acadia Pharmaceuticals and Saniona are advancing SAN2465, initially targeted for major depressive disorder (MDD), into Phase II trials. Although not currently in trials for Dup15q, SAN2465 is also being considered for addressing neuropsychiatric symptoms associated with the condition.
Despite challenges, the outlook for Dup15q syndrome treatment is gradually improving thanks to scientific advances, emerging partnerships, and strong community advocacy, which are collectively driving efforts toward potential disease-modifying therapies.
Chromosome 15q11.2-13.1 duplication syndrome (Dup15q syndrome) is a rare genetic condition caused by the duplication of a specific segment on the long arm of chromosome 15, specifically the 15q11.2-13.1 region. This segment is commonly duplicated in two forms: an extra isodicentric chromosome 15 [idic(15)] or an interstitial duplication [int dup(15)]. This area is also referred to as the "Prader-Willi/Angelman critical region (PWACR)" because of its involvement in both Prader-Willi and Angelman syndromes.
Dup15q syndrome typically presents with symptoms such as reduced muscle tone (hypotonia), delays in both gross and fine motor skills, varying degrees of intellectual disability, autism spectrum disorder (ASD), and epilepsy, including infantile spasms. The severity and range of symptoms can vary widely among individuals and are influenced by factors such as the number of duplicated copies and whether the duplication was inherited maternally or paternally.
Key Dup15q syndrome companies such as Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix, and others are evaluating new drugs for Dup15q syndrome to improve the treatment landscape.
Promising Dup15q syndrome therapies include Bexicaserin, UBE3A (ASO), and others.

Dup15q syndrome Overview

Myositis refers to inflammation of the muscles and is commonly linked with a group of inflammatory muscle diseases, including polymyositis, dermatomyositis, cancer-associated myositis, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). While *myositis* specifically involves inflammation, *myopathy* is a broader term encompassing any disease or disorder of the muscles, including but not limited to myositis.

This rare condition can impact not only the muscles but also various other organs, often resulting in significant reductions in quality of life. According to the American College of Rheumatology, inflammatory myopathies are autoimmune diseases in which the immune system mistakenly attacks healthy muscle tissue. Dermatomyositis and polymyositis are the most frequently occurring types within this group.

Dup15q syndrome Market Outlook

Supportive care for Dup15q syndrome involves personalized interventions based on individual needs. Physical and occupational therapy help with motor skill delays, while communication challenges are addressed using augmentative and alternative communication tools. Behavioral symptoms, especially those related to autism, can be managed through therapies like applied behavior analysis (ABA). For behavioral issues, psychotropic medications may be prescribed.

Currently, treatment development for Dup15q syndrome is limited, with only a few therapies in the pipeline. Lundbeck's bexacaserin targets developmental and epileptic encephalopathies (DEEs) but does not focus solely on Dup15q. Saniona's SAN2465, initially developed for major depressive disorder, shows promise for treating neuropsychiatric symptoms in Dup15q. Additionally, Quiver Bioscience is developing a preclinical therapy using antisense oligonucleotides (ASOs) to reduce UBE3A gene expression, which may help mitigate symptom severity.

Discover how the Dup15q syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dup15q syndrome Emerging Drugs
Bexicaserin: Lundbeck
UBE3A (ASO): Quiver Bioscience

Scope of the Dup15q syndrome Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dup15q syndrome Companies: Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix, and others
Key Dup15q syndrome Therapies: Bexicaserin, UBE3A (ASO), and others
Dup15q syndrome Therapeutic Assessment: Dup15q syndrome current marketed and Dup15q syndrome emerging therapies
Dup15q syndrome Market Dynamics: Dup15q syndrome market drivers and Dup15q syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Dup15q syndrome Unmet Needs, KOL's views, Analyst's views, Dup15q syndrome Market Access and Reimbursement

To know what's more in our Dup15q syndrome report, visit https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Dup15q syndrome Market Report:
Dup15q syndrome market report covers a descriptive overview and comprehensive insight of the Dup15q syndrome Epidemiology and Dup15q syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Dup15q syndrome market report provides insights into the current and emerging therapies.
The Dup15q syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Dup15q syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dup15q syndrome market.

Got queries? Click here to know more about the Dup15q syndrome market Landscape https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Dup15q syndrome Patient Share (%) Overview at a Glance
5. Dup15q syndrome Market Overview at a Glance
6. Dup15q syndrome Disease Background and Overview
7. Dup15q syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Dup15q syndrome
9. Dup15q syndrome Current Treatment and Medical Practices
10. Unmet Needs
11. Dup15q syndrome Emerging Therapies
12. Dup15q syndrome Market Outlook
13. Country-Wise Dup15q syndrome Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Dup15q syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Dup15q syndrome Market Outlook 2034 https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Dup15q syndrome Pipeline Insights, DelveInsight

"Dup15q syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dup15q syndrome market. A detailed picture of the Dup15q syndrome pipeline landscape is provided, which includes the disease overview and Dup15q syndrome treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.